Market Access & HEOR Consulting
- Organisations
- 7
Who covers which part of the pipeline
| Organisation | Pipeline Stage | Client Type | Psychedelic Focus |
|---|---|---|---|
| Analysis Group, Inc. | Market Access & HEORCommercialization & Launch | Drug DevelopersGovernment / Public Sector | Psychedelic-Adjacent Focus |
| Charles River Associates | Clinical DevelopmentMarket Access & HEORCommercialization & Launch | Drug DevelopersInvestors / Funds | Psychedelic-Adjacent Focus |
| Delphi | Market Access & HEORCommercialization & LaunchCare Delivery OperationsOrganizational Capability | Investors / FundsClinical Providers / Care OrganizationsGovernment / Public SectorNon-Profits / Advocacy OrganizationsDrug Developers | Explicit Psychedelic Focus |
| IQVIA Real World Data | Clinical DevelopmentRegulatory AffairsMarket Access & HEORCommercialization & Launch | Drug DevelopersResearch OrganizationsGovernment / Public Sector | Psychedelic-Adjacent Focus |
| L.E.K. Consulting | Clinical DevelopmentMarket Access & HEORCommercialization & Launch | Drug DevelopersInvestors / FundsClinical Providers / Care Organizations | Psychedelic-Adjacent Focus |
| Lumanity | Clinical DevelopmentMarket Access & HEORCommercialization & Launch | Drug Developers | Psychedelic-Adjacent Focus |
| The Sage Collective | Market Access & HEORCare Delivery OperationsCommercialization & Launch | Clinical Providers / Care OrganizationsResearch Organizations | Explicit Psychedelic Focus |
All Organisations
Analysis Group, Inc.
US-based economic consulting firm with published outcomes and cost-effectiveness analyses on esketamine treatment pathways relevant to payer decision-making and market access strategy.
Charles River Associates
Economic and strategy consultancy with life sciences advisory services, including published analysis on the evolving psychedelic therapeutics landscape and market implications.
Delphi
Delphi is a psychedelic healthcare consultancy focused on responsible integration into mainstream care. Led by Lia Mix and a cross-sector team, Delphi supports healthcare providers, investors, government agencies, and psychedelic organisations with strategy, education, and implementation guidance across regulation, delivery, and reimbursement. A major Delphi initiative is IHPI (Ibogaine Healthcare Policy Institute), a neutral, evidence-based, implementation-focused institute that develops coverage playbooks, health-economics models, and delivery blueprints for safe ibogaine adoption. Delphi also leads HOPE (Health Outcomes and Psychedelic Economics), a collaborative effort to generate independent economic evidence that can inform payer policy and broader healthcare access decisions.
IQVIA Real World Data
Commercial real-world data products and linked evidence assets used in life sciences research and regulatory support.
L.E.K. Consulting
Global strategy consultancy with US/EU healthcare practices and published analysis on psychedelic treatment pathways, funding dynamics, and commercialization implications.
Lumanity
Global commercialization and market access advisory firm with published commentary on positioning psychedelic medicines within biopharmaceutical development frameworks.
The Sage Collective
Purpose-led healthcare consultancy focused on integrating psychedelic-assisted therapy into health systems, with explicit services across strategic planning, implementation, reimbursement, and go-to-market execution.